I. bleeding were included. Among them, 646 (70%) had AVB and 139 (15%) had PUB. Use of NSAId, AAS and anticoagulants were all more frequent in PUB-group, and use of -blockers in AVB-group. Patients with PUB were older (63±13 vs 59±13, P= 0.001) and hypovolemic shock http://www.selleckchem.com/products/ink128.html was more frequent in those with AVB (29% vs 20%, P= 0.03). Parameters indicative of liver dysfunction and other baseline characteristics were similar in both groups. The rate of further bleeding was higher in AVB-group than in PUB-group (16% vs 7%, P< 0.01), as well as transfusion requirement

(2.9±3 vs 2.6±3, P= 0.03). The probability of 5-days survival without therapeutic failure was higher in PUB-group (93% vs 82%, P< 0.001). However, the probability of 42-days survival was similar in both groups (86% in PUB-group vs 83% in AVB-group, P= 0.42 by log-rank). Conclusions: Control of acute hemorrhage is better in cirrhotic patients with peptic ulcer bleeding than in those bleeding from esophageal varices. However, the probability of survival is similar in both groups. This suggests that with current therapies to control bleeding, other factors, such as liver dysfunction, determine survival. Disclosures: The following people have nothing to disclose: Alba Ardevol, Jose Castellote,

Joaquim Profitos, Carles Aracil, Josep Castellvi, Oana Pavel, Gemma Ibañez Sanz, Diana Horta, Josep M M. Calafat, Barbara Gomez-Pastrana, BGB324 ic50 Càndid Villanueva Background and aims: Insulin resistance and the metabolic syndrome have been associated with the severity of portal hypertension (PHT) in patients with cirrhosis. Response to non-selective betablockers (NSBBs) is evaluated by sequential measurements of the hepatic venous pressure gradient (HVPG), and defined as complete response (CR: decrease of HVPG≥20% or to absolute values<12mmHg), partial response (PR: HVPG decrease 10%-20%), or nonresponse (NR: HVPG decrease <10%). We aimed to assess the relationship between metabolic syndrome (MS) and hemodynamic response rate to NSBBs in patients with cirrhosis. Methods: We retrospectively

included MCE patients with paired HVPG measurements. MS was diagnosed by the International Diabetes Federation criteria in paients with obesity (body mass index –BMI >30kg/m2) presenting with at least two of the following critiria: (1) elevated tri-glycerides>150 mg/dL; (2) reduced HDL cholesterol<40 mg/ dL in males or <50 mg/dL in females; (3) arterial hypertension: systolic BP>130mmHg or diastolic BP>85mmHg; (4) elevated fasting plasma glucose >100mg/dL, or previously diagnosed type 2 diabetes. Patients with BMI>30kg/ m2 due to grade II/III ascites were not considered as having MS and excluded (n=5). Results: 278 patients with paired HVPG measurements were included (55.1% propranolol, 44.9% carvedilol). MS was diagnosed in 11.1% (31/278 patients), the proportion of patients treated with propranolol and carvedilol was similar in patients with MS (44.9% vs. 45.2%, p=0.87) as well as the doses of NSBBs (p=0.